We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd | NYSE:TAK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.25 | 1.91% | 13.36 | 4,280 | 11:52:41 |
From May 2023 to May 2024
By Ben Glickman
Takeda's treatment for a rare blood clotting disorder received approval from the U.S. Food and Drug Administration.
The FDA said Thursday it approved Adzynma, a genetically engineered protein product for enzyme replacement therapy, to treat adults and children with congenital thrombotic thrombocytopenic purpura.
The disorder, caused by a genetic mutation, causes blood clots to form in small blood vessels around patients' bodies and is estimated to affect fewer than 1,000 people in the United States.
Patients can have severe bleeding episodes, strokes or damage to organs, and the disease may be fatal if untreated.
The FDA said the efficacy and safety of Adzynma had been demonstrated in a study comparing the treatment to plasma-based therapies in patients with cTTP.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 09, 2023 15:10 ET (20:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Takeda Pharmaceutical Chart |
1 Month Takeda Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
